BOTOX Drug Profile
✉ Email this page to a colleague
Summary for Tradename: BOTOX
| High Confidence Patents: | 11 |
| Applicants: | 1 |
| BLAs: | 1 |
| Drug Prices: | Drug price information for BOTOX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BOTOX |
Recent Litigation for BOTOX
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Grant Prideco, Inc. v. Schlumberger Technology Corporation | 2023-02-27 |
| Teva Pharmaceuticals International GmbH v. Eli Lilly and Company | 2021-06-07 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Eli Lilly and Company | 2022-04-11 |
| 2017-02-21 |
Pharmacology for BOTOX
| Mechanism of Action | Acetylcholine Release Inhibitors |
| Physiological Effect | Neuromuscular Blockade |
| Established Pharmacologic Class | Acetylcholine Release Inhibitor Neuromuscular Blocker |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for BOTOX Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for BOTOX Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2017-07-15 | Company disclosures |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2013-12-28 | Company disclosures |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2013-12-28 | Company disclosures |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2013-12-28 | Company disclosures |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2017-07-15 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for BOTOX Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2033-03-11 | Patent claims search |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2039-02-26 | Patent claims search |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2039-02-26 | Patent claims search |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2034-03-16 | Patent claims search |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | ⤷ Subscribe | 2036-03-11 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for BOTOX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2018090633 | ⤷ Subscribe |
| Hong Kong | 1080377 | ⤷ Subscribe |
| Japan | 2007091756 | ⤷ Subscribe |
| Australia | 2005234633 | ⤷ Subscribe |
| Germany | 69434540 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BOTOX
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C02145629/01 | Switzerland | ⤷ Subscribe | FORMER OWNER: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, US |
| 122013000060 | Germany | ⤷ Subscribe | PRODUCT NAME: BOTULINUMTOXIN; NAT. REGISTRATION NO/DATE: IE/H/0113/001-003/II/077 20130131; FIRST REGISTRATION: FINNLAND IE/H/0113/001-003/II/077-FI 20130116 |
| 300563 | Netherlands | ⤷ Subscribe | DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT |
| 122008000042 | Germany | ⤷ Subscribe | PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531 |
| C300564 | Netherlands | ⤷ Subscribe | PRODUCT NAME: BOTULINUM TOXINE; NAT. REGISTRATION NO/DATE: RVG 32957RVG 17379RVG 32958 2012270627; FIRST REGISTRATION: NL 25449 20110822 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
BOTOX Market Analysis and Financial Projection Experimental
More… ↓
